

(12) (13) TWO MARYLAND CITIZENS WHO REPRESENT THE PERSPECTIVE OF PAIN PATIENTS, APPOINTED BY THE SECRETARY FROM A LIST SUBMITTED BY THE MARYLAND PAIN INITIATIVE.

(C) THE SECRETARY SHALL DESIGNATE THE CHAIR OF THE BOARD.

(D) (1) THE TERM OF A MEMBER APPOINTED BY THE SECRETARY IS 3 YEARS.

(2) IF A VACANCY OCCURS DURING THE TERM OF AN APPOINTED MEMBER, THE SECRETARY SHALL APPOINT A SUCCESSOR WHO SHALL SERVE UNTIL THE TERM EXPIRES.

(E) THE BOARD SHALL:

(1) MEET NOT FEWER THAN THREE TIMES ANNUALLY;

(2) MAKE RECOMMENDATIONS TO THE SECRETARY REGARDING THE DESIGN AND IMPLEMENTATION OF A PRESCRIPTION MONITORING PROGRAM, IN ACCORDANCE WITH THE PROVISIONS OF THIS SUBTITLE, INCLUDING RECOMMENDATIONS ABOUT:

(I) REGULATIONS AND THE NEED FOR ANY FURTHER LEGISLATION CONCERNING THE PROGRAM; AND

(II) SOURCES OF FUNDING, INCLUDING GRANT FUNDS UNDER THE HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM AND OTHER ~~FEDERAL OR STATE PROGRAMS, WITH THE OBJECTIVE OF AVOIDING ANY FEE OR ASSESSMENT AGAINST DISPENSERS OR PRESCRIBERS~~ SOURCES OF FEDERAL, PRIVATE, OR STATE FUNDS;

(3) (I) PROVIDE WITHIN 180 DAYS AFTER ITS FIRST MEETING, IN ACCORDANCE WITH § 2-1246 OF THE STATE GOVERNMENT ARTICLE, AN INTERIM REPORT TO THE GENERAL ASSEMBLY SETTING FORTH THE BOARD'S ANALYSIS AND RECOMMENDATIONS UNDER ITEM (2) OF THIS SUBSECTION REGARDING THE DESIGN, IMPLEMENTATION, AND FUNDING OF THE PROGRAM; AND

(II) PROVIDE ANNUALLY TO THE GOVERNOR AND, IN ACCORDANCE WITH § 2-1246 OF THE STATE GOVERNMENT ARTICLE, THE GENERAL ASSEMBLY AN ANALYSIS OF THE IMPACT OF THE PROGRAM ON PATIENT ACCESS TO PHARMACEUTICAL CARE AND ON CURBING PRESCRIPTION DRUG DIVERSION IN THE STATE, INCLUDING ANY RECOMMENDATIONS RELATED TO MODIFICATION OR CONTINUATION OF THE PROGRAM; AND

(4) PROVIDE ONGOING ADVICE AND CONSULTATION ON THE IMPLEMENTATION AND OPERATION OF THE PROGRAM, INCLUDING RECOMMENDATIONS REGARDING:

(I) CHANGES IN THE PROGRAM TO REFLECT ADVANCES IN TECHNOLOGY AND BEST PRACTICES IN THE FIELD OF ELECTRONIC HEALTH RECORDS AND ELECTRONIC PRESCRIPTION MONITORING; AND

(II) ~~EMERGING DRUGS OF CONCERN THAT SHOULD BE IDENTIFIED AS MONITORED PRESCRIPTION DRUGS; AND~~